Several checkpoint inhibitors that block PD-1, PD-L1 or CTLA-4 have been approved for therapy of solid cancers but, so far, checkpoint inhibitors have not shown convincing efficacy in MM [6–8]. Here, CD274 is linked to Miyoshi myopathy.